About

Dangerous viruses pose a global, persistent, and unavoidable threat to humanity.

What if we could predict which variants of a virus are of greatest concern and design vaccines to protect against them, a priori?

Many of the world’s most threatening viruses are continually evolving, outwitting our immune systems, outpacing efforts to develop effective vaccines, and causing untold suffering.

Our pioneering approach centers on a unique technology platform which allows us to survey the entire landscape of existing and potential variants to design new vaccines against the most threatening viruses.

Apriori was founded by Flagship Pioneering to provide humanity with variant-resilient protection against rapidly-evolving viruses.

Advisors

Jesse Bloom, PhD

Scientific Advisor

Professor, Fred Hutch

HHMI Investigator

Arup Chakraborty, PhD

Scientific Advisor and Academic Partner, Flagship Pioneering

Institute Professor at MIT

Founding Steering Committee Member, Ragon Institute

Ara Darzi, OM, KBE, PC, FRS

Special Advisor and Chairman, Preemptive Health & Medicine Initiative, Flagship Pioneering

Tom DiLenge

Senior Partner, Flagship Pioneering

Global Public Policy, Regulatory & Governmental Strategy

Stephen Hahn, MD

CEO-Partner, Flagship Pioneering and CEO, Harbinger Health

U.S. FDA Commissioner 2019-21

Kathrin Jansen, PhD

Former SVP and Head of Vaccines R&D, Pfizer

Michel C. Nussenzweig, MD, PhD

Scientific Advisor

Zanvil A. Cohn and Ralph M. Steinman Professor and Senior Physician, The Rockefeller University

HHMI Investigator

Wellington Sun, MD

Former Head of Vaccine Strategy, Moderna

Former Director, FDA Division of Vaccines

Andrew Weber

Senior Advisor

Former Assistant U.S. Secretary of Defense